Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 July 2021Website:
http://www.erasca.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 25 Oct 2024 20:02:19 GMTDividend
Analysts recommendations
Institutional Ownership
ERAS Latest News
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors
After reaching an important support level, Erasca, Inc. (ERAS) could be a good stock pick from a technical perspective. ERAS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares. All of the shares in the offering were sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, were approximately $184.0 million.
The Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are strong oral inhibitors that have the potential to be the top choice for treating RAS-mutated solid tumors.
Erasca, Inc. (Nasdaq: ERAS), a company focused on developing therapies for RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at $1.85 per share. The offering, expected to raise approximately $160 million before expenses, is set to close on May 21, 2024. Additionally, Erasca has granted the underwriters a 30-day option to purchase up to 12,972,972 additional shares at the offering price.
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company on Tuesday, January 9, 2024 at 9:00 am Pacific Time in Elizabethan Room D. Dr. Lim and David M. Chacko, M.D., chief financial officer and chief business officer, will also participate in one-on-one investor meetings.
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation of this combination will focus on EC-naïve patients based on promising initial activity
Fintel reports that on May 16, 2023, Goldman Sachs maintained coverage of Erasca (NASDAQ:ERAS) with a Buy recommendation.
What type of business is Erasca?
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
What sector is Erasca in?
Erasca is in the Healthcare sector
What industry is Erasca in?
Erasca is in the Biotechnology industry
What country is Erasca from?
Erasca is headquartered in United States
When did Erasca go public?
Erasca initial public offering (IPO) was on 16 July 2021
What is Erasca website?
https://www.erasca.com
Is Erasca in the S&P 500?
No, Erasca is not included in the S&P 500 index
Is Erasca in the NASDAQ 100?
No, Erasca is not included in the NASDAQ 100 index
Is Erasca in the Dow Jones?
No, Erasca is not included in the Dow Jones index
When was Erasca the previous earnings report?
No data
When does Erasca earnings report?
The next expected earnings date for Erasca is 08 November 2024